Developing novel and more effective treatments that improve quality of life for individuals with autism spectrum disorders is urgently needed. To date a wide range of behavioral interventions have been shown to be safe and effective for improving language and cognition and adaptive behavior in children and adolescents with ASD. However many people with ASD can receive additional benefit from targeted pharmacological interventions. One of the major drawback in setting up therapeutics intervention is the remarkable individual differences found across individuals with ASD. As a matter of fact the medications that are currently available address only symptoms associated with ASD and not the core domains of social and communication dysfunction. The pathogenesis paradigm shift of ASD towards synaptic abnormalities moved the research to pathway to disease that involve multiple systems and that are becoming the forefront of ASD treatment and are pointing toward the development of new targeted treatments. Some new therapeutics have been tested and others are being studied. In this context single gene disorders frequently associated with ASD such as Rett Syndrome, Fragile X and Tuberous Sclerosis have been of significant aid as neurobiology of these disorders is more clear and has a potential to shed light on the altered signaling in ASD. However much research is needed to further understand the basic mechanisms of disease and the relationship to idiopathic ASD. Clinical trials in children are underway with agents directed to core symptoms and to the associated disorders in the search of new therapeutics and progress are expected with possible new option for therapeutics in ASD in the upcoming future. Children and Adolescents with ASD and their families can provide important information about their experience with new treatments and this should be a priority for future research. In addition, research performed on genetic mouse models of ASD will keep on providing useful information on the molecular pathways dysrupted in the disease, thus contributing to identify novel drug targets.

Brain-immune interactions are essential to maintain health and their dysfunction contributes to diverse human diseases. Recent data show that haematopoietic processes and immune organs are under central autonomic control. Deficient regulation of inflammatory events contributes to brain diseases, whereas acute or chronic brain injury is linked with the development of systemic inflammatory conditions or immunosuppression. At present, common disorders with high socio-economic burden such as cancer, cardiovascular-, neuroinflammatory- and neurodegenerative diseases, asthma, allergies, autism, psychiatric conditions and sepsis are believed to be influenced, at least in part, by the dysfunction of brain-immune communication. Since the median age of the world's population is increasing rapidly, it is expected that the burden of common non-communicable diseases will further increase, which represents a huge challenge to the health care systems worldwide. Thus, there is an increasing demand to understand and treat complex diseases, many of which are age-related, and this is not possible unless the fine-tuned communication between large systems -such as the nervous and the immune system- is comprehensively understood. Although it is impossible to cover all areas of relevant research in this field, papers in this eBook give some insight to a few important aspects of brain-immune interactions and their contribution to disease. We hope that this collection could stimulate further relevant research and facilitate discussions to support the understanding of the highly complex interactions between the immune system and the brain in health and disease.

Vols. for 1963- include as pt. 2 of the Jan. issue: Medical subject headings.

The world is witnessing a burgeoning global epidemic of chronic cerebro- and cardiovascular disease and depression disorders. The reader will find this comprehensive book to be a long-needed, up-to-date knowledge base on these increasingly recognized comorbid conditions that have long-term consequences for individual function and well-being and society in general. This comprehensive book outlines the complex and bidirectional relationship between various types of depression and cerebro- and cardiovascular diseases. It is written by a range of experts in the field, including psychiatrists, cardiologists, neuroscientists, psychologists, and epidemiologists, with the aim of presenting and discussing the most recent evidence on the pathophysiology, neurobiology, and clinical presentation of these common and disabling comorbid conditions and the available pharmacological, psychological, and behavioral interventions. By elucidating the underlying clinical and neurobiological mechanisms in the brain and the rich interplay between the body and the brain biology, the book brings together the latest knowledge of this overlapping area in Psychiatry and Cardiology. The clear descriptions of evidence-based approaches to clinical treatment ensure that it will serve as both an up-to-date overview and a future guide for practicing clinicians and graduate students.

The Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker of cell injury. Based on the author's original discovery of the charnoly body in the developing, undernourished rat cerebellar Purkinje neurons, this book delves into the potential for utilizing this mitochondria and lysosomal-derived intracellular organelle as a nanotheranostic biomarker to prevent and cure various diseases. The book discusses the cellular, molecular, genetic, and epigenetic mechanisms of charnolosomes and charnolosome-derived nano-vesicles. It also investigates the molecular mechanisms underlying auto-inflammatory, autoimmune, and infectious diseases resulting from their compromised mitochondrial bioenergetics, and the potential use of the charnolosome in preventing and curing such conditions. - Shares the latest knowledge on the charnolosome and charnolosome-derived nano-vesicles and their significance at a cellular and molecular level - Considers the charnolosome in relation to a range of conditions, including neurodegenerative, metabolic, and multi-drug resistant systemic diseases - Presents future perspectives of the charnolosome in personalized nanotheranostics

Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research. This volume reviews existing theories and current research surrounding the movement disorder Dyskinesia. - Leading authors review state-of-the-art in their field of investigation and provide their views and perspectives for future research - Chapters are extensively referenced to provide readers with a comprehensive list of resources on the topics covered - All chapters include comprehensive background information and are written in a clear form that is also accessible to the non-specialist

The Rose-Mackay Textbook of Autoimmune Diseases, Seventh Edition is a comprehensive reference that emphasizes the "3 P's" of 21st Century medicine: precision, prediction, and prevention. Topics cover the modern systems approach to biology that involves large amounts of personalized, ongoing physiologic data ("omics") coupled with advanced methods of analysis, new tests of genetic engineering, such as CRISPR, auto inflammatory diseases, autoimmune responses to tumor immunotherapy, and information on normal immune response and disorders. Each of the major autoimmune disorders is discussed by researchers and clinical investigators experienced in dealing with patients. This new edition continues its success with 75% of the content revised, updated, or completely new. This edition is a valuable resource to clinicians involved in the diagnosis and treatment of autoimmune disease, as well as to scientists who want to follow developments in the field. - Provides new research on autoimmune diseases, their diagnosis, prevention, and therapy - Covers a complete range of all common, rare and new autoimmune diseases, including cancer and COVID - Extensively revised with 75% new material based on autoimmunity, developments in the different diagnosis and therapies for these autoimmune diseases, and a completely updated description of the different diseases - Supplemented with a website that hosts a Podcast per chapter